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Induced pluripotent stem cells (iPSCs) are artificially derived from somatic cells that have been 
transduced with defined reprogramming factors. A previous report has indicated the possibility 
of using iPSCs as an immune stimulator to generate antigen-specific immunity. In our current 
study, we have investigated whether human iPSCs (hiPSCs) have the ability to enhance specific 
immune response against a human immunodeficiency virus type 1 (HIV-1) antigen in a xenogenic 
mouse model. Our results show that BALB/c mice immunized with hiPSCs transduced with an 
adenoviral vector encoding HIV-1 gp160 exhibited prominent antigen-specific cellular immune 
responses. We further found that pre-treatment of hiPSCs with ionizing radiation promotes 
the secretion of pro-inflammatory cytokines such as interleukin-1 alpha (IL -1α), IL -12, and IL -18. 
These cytokines might promote the activation of antigen-presenting cells and the effective 
induction of cellular immunity. Our present findings thus demonstrate that a hiPSCs-based 
vaccine has the potential to generate cellular immunity against viral antigens such as HIV-1 
gp160 in a xenogenic condition.
Keywords: human induced pluripotent stem cells, ionizing radiation, pro-inflammatory cytokine, cellular immunity, 
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of individual-specific pluripotent stem cells that are valuable 
for personalized cell transplantation therapy without concern 
for immune rejection.
A recent report has demonstrated a new application of hiP-
SCs as an immune stimulator. Li et al. (2009b) demonstrated that 
the inoculation of human ES cells (ESCs) or hiPSCs can induce a 
protective immune response against murine colon cancer cells. It 
is considered that the pluripotent stem cell induces the immune 
response in vivo against colon cancer cells expressing oncofetal 
antigens that are present in normal stem cells (Li et al., 2009b). 
Moreover,  other  studies  demonstrated  that  ESCs  can  produce 
pro-inflammatory cytokines and growth modulators following a 
treatment with ionizing radiation (Guo et al., 2006). We therefore 
hypothesized that irradiated hiPSCs expressing the HIV-1 antigen 
have a potency to induce the antigen-specific CTL response.
In our current study, we selected HIV-1 gp160 as a model antigen 
for evaluating the ability of hiPSCs as a vaccine vector. Our cur-
rent results provide evidence for the capacity of hiPSCs to induce 
antigen-specific immunity against viral proteins.
Materials and Methods
Cell Culture
Human  induced  pluripotent  stem  cells  (hiPSCs)  were  derived 
from adult human fibroblasts and were obtained from the RIKEN 
Bioresource  Center  (clone  no.  201B7;  Takahashi  et  al.,  2007). 
The hiPSCs were cultured on plates coated with Matrigel (BD 
Biosciences, San Jose, CA, USA) and maintained in Knockout 
Dulbecco’s  modified  Eagle’s  medium  (Invitrogen,  Carlsbad, 
CA, USA) supplemented with 20% Knockout SR (Invitrogen), 
1% GlutaMAX (Invitrogen), 100 μM non-essential amino acids 
(Invitrogen), 50 μM β-mercaptoethanol, and 10 ng/ml human 
introduCtion
The latest estimate indicates that 33.4 million people are living with 
human immunodeficiency virus (HIV)/AIDS in 2009, and there are 
some 2.7 million new infections each year. Globally, HIV/AIDS is 
the leading cause of mortality among younger people and children 
where 2.0 million people die annually. The development of a safe 
and effective HIV/AIDS vaccine is required urgently to halt this 
epidemic. There is currently no effective AIDS vaccine available 
(McElrath and Haynes, 2010).
Current approaches in the development of HIV/AIDS vac-
cines have focused not on preventing infection itself, but on 
eliciting potent antiviral-specific CD8+ T cell [cytotoxic T lym-
phocyte (CTL)] responses to limit viral replication (Yamamoto 
and Matano, 2008). This is in part because such an immune 
response  contributes  to  non-progression  of  AIDS  in  people 
infected with HIV type 1 (HIV-1). It is thus desirable to develop 
a new vaccine vector system for generating effective CTL response 
against HIV-1.
Recently,  reprogramming  of  human  somatic  cells  into 
pluripotent embryonic stem (ES) cell-like cells, termed human 
induced pluripotent stem cells (hiPSCs) has been successfully 
achieved by the transduction of four defined transcription factors 
(Klf4, Oct4, Sox2, and c-Myc; Takahashi and Yamanaka, 2006; 
Takahashi et al., 2007; Park et al., 2008). This technology does not 
require embryos or oocytes, thereby facilitating the generation 
Abbreviations: APC, antigen-presenting cell; CAG promoter, CMV enhancer/β-
actin promoter with β-actin intron; DsRed, Discosoma sp. red fluorescent protein; 
hiPSC, human induced pluripotent stem cell; HIV, human immunodeficiency vi-
rus; IL-1, interleukin-1; MHC, major histocompatibility complex; NF-κB, nuclear 
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(s.c.) with 5 × 105 15 Gy-irradiated or formalin-fixed (2%, 15 min) 
  hiPSCs expressing either DsRed or HIV-1 gp160, three times at 2- or 
4-week intervals. The study was approved by the Animal Administer 
Community of Yokohama City University.
tetraMer assay
Tetramer assay is a well-established way to examine the antigen-
specific CTL in mouse models (Villacres et al., 2000; Hovav et al., 
2007). Peptide 18 (p18: RGPGRAFVTI) derived from the V3 loop 
of HIV-1IIIB gp160 is an epitope recognized by CTL in the BALB/c 
mouse (H-2Dd) model immunized with HIV-1IIIB gp160 protein 
(Takahashi et al., 1988). H-2Dd/p18 tetramer was tetrameric H-2Dd 
major histocompatibility complex (MHC) class I with the p18 
labeled with phycoerythrin (PE) synthesized by NIH Tetramer 116 
Core Facility (Atlanta, GA, USA). The number of CD8+ T cells 
expressing  T  cell  receptor  (TCR)  that  recognized  H-2Dd/p18 
tetramer was examined by tetramer assay. Tetramer assays were 
performed using a H-2Dd/p18 tetramer as previously described 
(Shimada et al., 2010). Briefly, PBMCs were isolated from immu-
nized mice, and stained with a PE-conjugated H-2Dd/p18 tetramer 
and FITC-conjugated anti-mouse CD8a antibody. The cells were 
then analyzed by flow cytometry (FACSCantoII).
intraCellular Cytokine staining assay
Intracellular cytokine staining (ICS) assays were performed as 
previously described (Shimada et al., 2010). Briefly, PBMCs were 
obtained from immunized mice, and the red blood cells were 
removed using lysing buffer (BD Bioscience). The lymphocytes were 
incubated with p18 (RGPGRAFVTI) from the V3 loop of HIV-1IIIB 
gp160 protein, and treated with BD GolgiStop (BD Bioscience) for 
6 h at 37°C. The cells were then stained with FITC-conjugated anti-
mouse CD8a antibody, suspended in cytofix/cytoperm solution 
(BD Bioscience), and incubated with the PE-conjugated anti-mouse 
interferon-gamma (IFN-γ) antibody (XMG1.2; eBioscience). The 
cells were subsequently analyzed by flow cytometry (FACSCantoII) 
utilizing FACSDiva software.
rt-PCr
Total RNA was isolated by TRIzol reagent (Invitrogen), and reverse-
transcribed using ReverTra Ace (Toyobo, Osaka, Japan) in accord-
ance with the manufacturer’s instructions. The resulting cDNAs 
were amplified with Ex Taq DNA polymerase (Takara Bio, Otsu, 
Japan). To quantify the cytokine RNA levels, a SYBR premix Ex Taq 
II (Takara Bio) was used and analyses were performed using the 
ABI PRISM Sequence Detector System 7500 (Applied Biosystems, 
Foster City, CA, USA). The primer sets used for RT-PCR were 
as  follows:  interleukin  (IL)-1α:  5′-tcgagccaatgatcagtacc-3′  and 
5′-tggtctcactacctgtgatg-3′; IL-18: 5′-gaccaagttctcttcattgacc-3′ and 
5′-tgtcctgggacacttctctg-3′; IL-12A: 5′-atgatggccctgtgccttag-3′ and 
5′-gtggcacagtctcactgttg-3′;  Oct4:  5′-gagatatgcaaagcagaaacc-3′ 
and 5′-cttcactgcactgtactcct-3′; Nanog: 5′-atggttggagcctaatcagc-3′ 
and 5′-tgttgtccttagcagccaag-3′; hTERT: 5′-ccgtacatgcgacagttcg-3′ 
and  5′-caagaaatcatccaccaaacg-3′,  and  glyceraldehydes-3-
  phospate  dehydrogenase  (gapdh):  5′-ccatggagaaggctgggg-3′  and 
5′-caaagttgtcatggatgacc-3′. The IL-1α, IL-18, or IL-12A transcripts 
were normalized using the gapdh expression levels, and analyzed 
by the comparative CT method.
basic fibroblast growth factor (bFGF) and conditioned medium 
for mouse embryonic fibroblasts. MRC5 (human fetal lung fibrob-
lasts) and RAW 264.7 (mouse monocyte/macrophage) cell lines 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; 
Wako, Osaka, Japan) supplemented with 10% heat-inactivated fetal 
bovine serum.
adenovirus veCtor
The adenovirus vectors expressing HIV-1 Rev and Env gp160 pro-
teins (Ad-gp160) or Discosoma sp. red fluorescent protein (DsRed, 
Ad-Red) were generated as described previously (Abe et al., 2009). 
These adenoviral vectors are replication-defective recombinant 
adenovirus type 5 virus lacking the E1 and E3 regions (Mizuguchi 
and Kay, 1998). The expression of HIV-1 rev-env gp160, or DsRed 
was controlled using the CMV enhancer/β-actin promoter with 
β-actin intron (CAG promoter). These vectors were propagated in 
HEK293 cells and purified by two repetitions of the CsCl method 
as described elsewhere (Lieber et al., 1996). The total concentra-
tion of virions in each preparation was calculated from the optical 
density at 260 nm (OD260), using the formula 1 OD260 = 1 × 1012 
viral particle (vp)/ml.
antibodies and iMMunoblotting
HiPSCs were transduced with Ad-gp160 or Ad-Red at 3,000 vp/cell 
for 24 h. The cellular lysates were then subjected to immunoblotting 
analysis with anti-HIV-1 gp120, anti-HIV-1 gp41 (AIDS Research 
and Reference Reagent Program, NIH, MD, USA), anti-Oct4 (C-10; 
Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA),  anti-SOX2 
(Millipore, Billerica, MA, USA), anti-phosphorylated IκB-α (Active 
Motif, Carlsbad, CA, USA), anti-IκB-α (Santa Cruz Biotechnology) 
or anti-β-actin monoclonal antibodies (AC-15; Sigma, Saint Louis, 
MO, USA). Immunoblotting images were acquired using LAS3000 
(Fujifilm, Tokyo, Japan).
Flow CytoMetry analysis
HiPSCs and MRC5 fibroblasts were harvested with 0.02% EDTA 
in phosphate buffered saline (PBS), dissociated into single cells, 
and stained with the fluorescein isothiocyanate (FITC)-conjugated 
anti-HLA-ABC antibody (W6/32; BioLegend, San Diego, CA, USA). 
The cells were then analyzed by flow cytometry (FACSCantoII, BD 
Biosciences). For the evaluation of effector CD8+ T cells, periph-
eral blood mononuclear cells (PBMCs) from immunized mice 
were  stained  with  phycoerythrin/cyanin7  (PE-Cy7)-conjugated 
anti-mouse CD62L (MEL-14; BioLegend) and FITC-conjugated 
anti-mouse CD8a antibodies (Ly-2; eBioscience, San Diego, CA, 
USA) without stimulation. The cells were then analyzed by flow 
cytometry (FACSCantoII). CD62L− CD8+ T cells were defined as 
effector CD8+ T cells.
aniMal iMMunization
Generally, to estimate cell-based vaccine, 1 × 105 to 1 × 106 cells 
were inoculated into a mouse (Yoon et al., 2008; Li et al., 2009a; 
Senju et al., 2009). We thus introduced 5 × 105 cells in this immu-
nization. We employed immunization protocol described as fol-
lows. Eight-week-old female BALB/c mice (H-2Dd) were purchased 
from Japan SLC Inc. (Shizuoka, Japan) and housed in an animal 
facility. Under anesthesia, these mice were injected subcutaneously www.frontiersin.org  February 2011  | Volume 2  | Article 27  |  3
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aberrant cell differentiation (Tashiro et al., 2010). We thus utilized a 
replication-defective human adenovirus type 5 vector encoding either 
HIV-1 gp160 (Ad-gp160) or DsRed (Ad-Red) under the control of 
the CAG promoter. We detected the successful expression of HIV-1 
gp160 in hiPSCs by immunoblotting with either anti-HIV-1 gp41 or 
anti-HIV-1 gp120 antibodies (Figure 1A). Flow cytometric analysis 
further revealed that >90 and 60% of the transduced hiPSC popula-
tion expressed DsRed and HIV-1 gp160, respectively (Figure 1B).
enzyMe-linked iMMunosorbent assay
The culture supernatants were collected from the irradiated hiPSCs 
at 24-h post-irradiation, centrifuged to remove cellular debris prior 
to filtration, and then subjected to enzyme-linked immunosorbent 
assay (ELISA) in accordance with the manufacturer’s instructions 
(R&D Systems, Minneapolis, MN, USA).
aCtivation oF Mouse sPlenoCytes with hiPsCs
Activation of mouse splenocytes with hiPSCs was detected by the 
co-culture  system.  Generally,  the  cell-to-cell  co-culture  system 
employs from 1:1 to 1:10 in the ratio of effector cells to target cells in 
number (Maitra et al., 2004; Hall et al., 2008). HiPSCs (2 × 105 cells) 
were co-cultured with mouse splenocytes (2 × 106 cells) from naive 
mouse, at a ratio of 1:10. We employed the assay protocol described 
previously (Yoon et al., 2008). In brief, 200,000 hiPSCs were treated 
by either 15 Gy-irradiation or 2% formalin solution for 15 min, and 
then co-cultured or cultured in transwells (pore size, 0.4 μm) with 
2 × 106 BALB/c mouse splenocytes for 40 h. The splenocytes were 
then stained with FITC-anti-mouse CD11c (HL3; BD Bioscience) 
and PE-anti-mouse CD86 (PO.3; eBioscience) or PE-anti-mouse 
MHC class II antibodies (M5/114.15.2; eBioscience). The cells were 
analyzed under flow cytometry (FACSCantoII) utilizing FACSDiva 
version 6.1.2 software.
MiCroarray analysis
Total RNAs for microarray analysis were isolated from hiPSCs cul-
tured at 14 h post-irradiation with TRIzol (Invitrogen) and then 
analyzed using the Affymetrix GeneChip Human Genome U133 
Plus 2.0 Array and GeneChip Scanner 3000. The gene expression 
levels were compared between irradiated hiPSCs and the non-
treated control hiPSCs. Up-regulated genes showing at least a two-
fold change were identified using DNA MicroArray Viewer Software 
(Kurabo, Osaka, Japan).
MeasureMent oF nuClear FaCtor-kaPPa b aCtivation
The culture supernatant was recovered from the irradiated hiPSCs 
at 24-h post-irradiation. To neutralize IL-1α in the culture superna-
tant, anti-human-IL-1α-neutralizing antibody (PeproTech, Rocky 
Hill, NJ, USA) or rabbit sera as control were added at 0.1 or 1 μg/
ml. Two hours after incubation, RAW 264.7 cells were incubated 
with the culture supernatants for 10 min. Cell lysates were then 
immunoblotted with anti-phosphorylated IκB-α (Active Motif) 
or anti-IκB-α antibodies (Santa Cruz Biotechnology).
statistiCal analyses
We  performed  the  experiment  with  n  =  3.  All  values  are 
expressed as mean ± error. Statistical analyses were performed 
using Mann–Whitney’s U-test with StatView 5.0 software (SAS 
Institute Inc., Cary, NC, USA), and P < 0.05 was considered to be 
statistically significant.
results
transduCtion oF undiFFerentiated huMan iPsCs with an 
adenovirus veCtor exPressing hiv-1 gp160
We  initially  investigated  the  efficient  gene  transfer  into  hiPSCs. 
Previous reports indicated that the CAG-promoter-driven adenovi-
ral vector system can effectively transduce genes into hiPSCs without 
Figure 1 | expression of HiV-1 gp160 in hiPSCs. (A,B) hiPSCs were 
transduced with adenoviral vectors encoding HIV-1 gp160 (3,000 vp/cell) or 
DsRed (3,000 vp/cell) for 24 h. The HIV-1 gp160 protein and its cleaved product 
(gp41 and gp120) were detected by immunoblotting against anti-HIV-1 gp41 
[(A) left] or anti-HIV-1 gp120 antibodies [(A) right]. β-actin was used as the 
internal control. The expression of DsRed or HIV-1 gp160 protein was 
measured by flow cytometry (B). The staining patterns of transduced (thick 
line) and non-transduced (thin line) cells are shown. Percentages of 
positive-cells after transduction with each adenoviral vectors are also 
indicated. (C) iPSC markers (Oct4, Nanog, and hTERT) and GAPDH mRNAs 
were detected in, MRC5 fibroblasts, non-transduced hiPSCs or Ad-gp160-
transduced hiPSCs at 24 h by RT-PCR. (D) The iPSC markers Oct4 and SOX2, 
and HIV-1 gp160 proteins were detected by immunoblotting of MRC5 
fibroblasts, non-transduced hiPSCs, and Ad-gp160-transduced hiPSCs.Frontiers in Microbiology  | Virology    February 2011  | Volume 2  | Article 27  |  4
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the sera from mice injected with irradiated hiPSCs (Figure 2G). 
Furthermore, the sera from mice immunized with formalin-fixed 
hiPSCs-gp160 but not with irradiated hiPSCs, contained antibod-
ies against cell surface antigens of hiPSCs itself as revealed by flow 
cytometry (Figure 2H).
These  results  indicate  that  formalin-fixed  hiPSCs-gp160-
  immunized mice were induced with antibodies against HIV-1 
gp160 and against cell surface antigens of hiPSCs. The latter anti-
bodies have the potential to rapidly eradicate hiPSCs-based vaccines 
during immunization in mice. Whereas, irradiated hiPSCs induced 
more antigen-specific CD8+ T cells than formalin-fixed hiPSCs and 
less antibody against hiPSCs.
irradiated hiPsCs stiMulate Cd11c+ sPlenoCytes through a 
ContaCt-indePendent MeChanisM using soluble MoleCules
We next addressed whether irradiated hiPSCs could modulate the 
activity and function of immune cells such as antigen-presenting 
cells (APCs). Splenocytes from a BALB/c mouse were co-cultured 
with either formalin-fixed hiPSCs or irradiated hiPSCs, and then 
examined by flow cytometry for the expression of the activation 
marker CD86 or MHC class II in CD11c+ cells. Upon co-culture with 
irradiated hiPSCs, but not with formalin-fixed cells, the expression 
levels of both CD86 and MHC class II were significantly increased 
in the CD11c+ cell population (Figures 3A,B).
To further investigate whether the stimulatory effects of irradi-
ated hiPSCs upon CD11c+ cells were dependent on cell-to-cell inter-
actions or soluble factors, transwell experiments were performed. 
HiPSCs and mouse splenocytes were separately cultured in the 
lower and upper chambers of a transwell, and then analyzed for the 
expression of activation markers on CD11c+ cell. Our results showed 
that these activation markers were indeed induced in the transwell 
system in a similar manner to the co-culture system (Figures 3C,D). 
We thus concluded that soluble factors from irradiated hiPSCs play 
a role in their stimulatory effects upon CD11c+ cells.
induCtion oF Pro-inFlaMMatory Cytokines in hiPsCs by 
radiation
To identify the soluble factors that are secreted from irradiated 
hiPSCs, we performed a DNA microarray experiment to screen 
for ionizing radiation-induced factors in these cells. Total RNAs 
extracted from irradiated or untreated hiPSCs were subjected to 
DNA microarray analysis. Following data normalization, we selected 
genes that were induced more than two-fold upon exposure to ion-
izing radiation (Figure 4A). We found that multiple cytokines were 
up-regulated in hiPSCs by ionizing radiation. In particular, pro-
inflammatory cytokine IL-1α and T helper type 1 (Th1)-related 
cytokines IL-12A and IL-18 were prominently induced under these 
conditions. The expression of these cytokines was further analyzed 
by either conventional RT-PCR or quantitative RT-PCR (qPCR). 
Consistent with the microarray data, IL-1α, IL-12A, and IL-18 genes 
were found to be significantly increased at 24 h after irradiation 
(5.00-, 2.50-, and 2.46-fold, respectively; Figures 4B,C). Notably, 
the expression of these cytokines was not induced by an adenovi-
rus infection (data not shown). We next investigated whether the 
cytokines production/induction was observed in MRC5 fibroblasts 
following ionizing irradiation. We found that there was little induc-
tion of IL-12A and IL-18 following the irradiation. Furthermore, 
We next addressed whether hiPSCs would retain their pluripo-
tency following the transduction of exogenous genes. RT-PCR 
analysis revealed that the iPSC markers Oct4, Nanog, and hTERT 
were strongly expressed in the cells before and after the transduc-
tion of HIV-1 gp160, but this was not the case in MRC5 fibroblasts 
(Figure 1C). Moreover, the protein expression of Oct4 and SOX2 
was also detectable in Ad-infected hiPSCs during immunoblotting 
analysis (Figure 1D).
iMMunization with hiPsCs and the iMMune resPonses 
generated
We investigated whether hiPSCs could induce cellular immune 
response against the viral antigen in a mouse model. Before immu-
nization, flow cytometric analysis confirmed that hiPSCs expressed 
an extremely low level of MHC class I as compared with MRC5 
fibroblasts on cell surfaces (Figure 2A), suggesting the minimum 
xenogenic reaction in a mouse inoculated with hiPSCs.
We next generated a formalin-fixed and irradiated hiPSCs-based 
vaccine expressing HIV-1 gp160. Because cell differentiation can 
be paralleled with cell proliferation as asymmetric cell division 
(Morrison and Kimble, 2006), the formalin-fixation or irradiation 
can abrogate both cell growth and differentiation (Figure 2B). To 
examine whether hiPSCs expressing HIV-1 gp160 could stimulate 
an immune response, we immunized immunocompetent BALB/c 
mice with either formalin-fixed or irradiated hiPSCs expressing 
HIV-1  gp160  (hiPSCs-gp160)  or  DsRed  (hiPSCs-Red).  These 
mice were boosted twice on days 15 and 40 (Figure 2C). In this 
protocol, the immunized mice did not show any clinical signs 
of adverse effects accompanied by xenogenic immune reaction 
such as skin rash, arthritis, or overt organ dysfunction (data not 
shown). On days 0, 7, 22, and 47 after the first immunization, we 
performed the well-  established H-2Dd/p18 tetramer-binding assay. 
P18 (RGPGRAFVTI) is an epitope recognized by CTL in BALB/c 
mouse (H-2Dd) model immunized with HIV-1IIIB gp160 protein 
(Takahashi et al., 1988). This assay measures CD8+ T cells recog-
nizing the H-2Dd-restricted p18 derived from the V3 loop of the 
HIV-1IIIB gp160 protein. At the same time, we conducted an ICS 
assay to detect cellular IFN-γ expression following stimulation with 
the p18. The results showed that p18 antigen-specific CD8+ T lym-
phocytes were substantially induced in mice injected with irradiated 
hiPSCs-gp160 as compared with other groups. It was statistically 
significant on Day 47 (Figure 2D). Although boost effects such as 
clonal expansion of p18-specific CD8+ T cells were not observed 
in mice after booster immunization with the hiPSC-based vac-
cine, antigen-specific IFN-γ-producing CD8+ T lymphocytes were 
significantly increased up to 47 days in mice immunized with irra-
diated hiPSCs-gp160 further than the other groups (Figure 2E). 
Moreover, the proportion of total effector CD8+ T lymphocytes 
(CD62L− CD8+ cells) was also found to be substantially increased 
by the immunization with irradiated hiPSCs-gp160 (Figure 2F).
We next examined the induction of HIV-1 gp160-specific anti-
bodies in the sera from immunized mice by immunoblotting. We 
tested the immunoreactivity of the sera against cell lysates from 
either control 293T cells or those expressing HIV-1 gp160. We 
found that sera from mice immunized with formalin-fixed hiPSCs-
gp160 contained antibodies that targeted the HIV-1 gp160 protein 
and its cleavage product, gp41, whereas this was not the case for www.frontiersin.org  February 2011  | Volume 2  | Article 27  |  5
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level upon irradiation (Figure 4E), whereas IL-12 and IL-18 were 
not detectable by ELISA (data not shown). We further analyzed 
the biological function of IL-1α secreted from irradiated hiPSCs to 
mouse immune cells using a mouse monocyte/macrophage cell line 
RAW 264.7. Activation of RAW 264.7 was monitored by measur-
ing of IκB-α phosphorylation. Cell supernatants from   irradiated 
MRC5 fibroblasts did not express IL-1α irrespective of the irradia-
tion (Figure 4D). These results indicate that hiPSCs can efficiently 
produce these cytokines after irradiation.
We next examined the cytokine production levels from irradi-
ated hiPSCs. Culture supernatants from these cells were collected 
and analyzed by ELISA. We found a substantial increase in the IL-1α 
Figure 2 | Antigen-specific immunity in mice immunized with hiPSCs 
expressing gp160. (A) MRC5 fibroblasts and hiPSCs were stained with the 
anti-HLA-ABC antibody followed by flow cytometry. Note that MHC class I 
expression in hiPSCs was extremely low compared with MRC5. (B) Pre-
treatment of hiPSCs before vaccination. hiPSCs were infected with adenoviral 
vector encoding either HIV-1 gp160 or DsRed before inoculation. Cells were 
then irradiated with 15 Gy or fixed with 2% formalin solution prior to the 
vaccination (C) This diagram indicates a protocol for mouse immunization with 
hiPSCs. (D,e) Female BALB/c mice (8–10 weeks old) were inoculated s.c. with 
PBS, 5 × 105 formalin-fixed hiPSCs-gp160 (gp160 FF), irradiated hiPSCs-gp160 
(gp160 IR) or irradiated hiPSCs-Red (DsRed IR) and then boosted twice with the 
same cell groups on days 15 and 40 after the first immunization. Antigen-specific 
CD8+ T lymphocytes were measured via a H-2Dd/p18 tetramer-binding assay 
(D). PBMCs from immunized mice were stimulated with the p18 peptide 
derived from the V3 loop of HIV-1 gp160 and then treated with BD Golgistop for 
6 h. HIV-specific IFN-γ-producing CD8+ T lymphocytes were measured by flow 
cytometry with anti-CD8a-FITC and anti-IFNγ-PE (e). Arrows indicate the day of 
immunization. (F) PBMCs were collected 7 days after the first immunization and 
stained with anti-CD62L -PE-Cy7 and anti-CD8a-FITC antibodies without 
stimulation. Effector CD8+ T lymphocytes (CD62L− CD8+) were measured by 
flow cytometry. (g) Immunoblotting analysis with immunized mouse sera 
against total cell lysates from 293T cells transfected with empty vector (EV) or 
HIV-1 gp160 expressing plasmid. (H) Non-permeabilized hiPSCs were stained 
with pooled sera from mice immunized with formalin-fixed or irradiated 
hiPSCs-gp160 and then stained with FITC-anti-mouse immunoglobulin G (IgG) 
antibody followed by flow cytometry. Staining patterns obtained for the pooled 
sera (thick line) or control (thin line) are shown. All data are the mean ± error of 
three mice per group. *P < 0.05.Frontiers in Microbiology  | Virology    February 2011  | Volume 2  | Article 27  |  6
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amount of cell death in primary cultures (data not shown). Thus 
the adenoviral vector system is suitable for use with hiPSCs owing 
to its high transduction efficiency and low cellular toxicity.
Our  current  immunization  protocol  demonstrated  that  the 
boost stimulation with irradiated hiPSCs-gp160 did not induce the 
clonal expansion of antigen-specific CD8+ T cells. Unlike the vaccine 
model with viral vectors, boost effects are usually not obvious in 
cell-based vaccines (Li et al., 2009a). However, a boost stimulation 
can prolong the long-standing immune response against antigens. 
Consistently, our current hiPSCs vaccine system can induce rela-
tively high levels of antigen-specific CD8+ T cells in the long term. 
This could be an advantage of the hiPSCs-based vaccine although 
further analytical and experimental studies are required to better 
understand and evaluate the vaccine system.
The immunization of mice with irradiated hiPSCs causes the 
induction of cellular immunity rather than humoral immunity, 
which is in contrast to the result of immunization with formalin-
fixed hiPSCs. Previous studies have suggested that Th1- and Th2-cells 
direct different immune response pathways (Kidd, 2003). Our present 
data indicates that irradiated hiPSCs may induce Th1-cytokines that 
contribute to the Th1 shift in immunized mice resulting in the induc-
tion of antigen-specific CTL. Furthermore, pre-treatment with ion-
izing radiation could reduce the generation of antibodies against 
the hiPSC vector itself. Thus, ionizing irradiation might be a proper 
procedure in the hiPSCs-based vaccine system.
In our current study, we evaluated the ability of hiPSCs to induce 
antigen-specific CTL as a cell-based vaccination in a xenogenic mouse 
model. In fact, a previous report presented by Li et al. (2009b) dem-
onstrates that hiPSCs can produce a tumor antigen-specific immune 
reaction leading to a tumor rejection even in a xenogenic condition. 
It has been reported that MHC molecules could strongly induce 
xenogenic immune reactions. As we and others have revealed, hiPSCs 
express a very low level of MHC molecules on the cell surface (Suarez-
Alvarez et al., 2010). With this knowledge in hand, we decided to use 
the mouse model of HIV-1 gp160 to assess the ability of hiPSCs as 
a cell-based vaccine vector. However, it is necessary to investigate 
the involvement of the xenogenic condition in the antigen-specific 
immune reaction by the iPSCs-mediated vaccination.
We investigated the MHC-restricted immune response in the 
xenogenic mouse model in this report. It is likely that inoculated 
hiPSCs could be phagocytosed by mouse APCs such as dendritic cells 
followed by the antigen presentation and MHC-restricted immune 
activation in an immunized mouse. However, a previous report 
indicates that pluripotent stem cells such as ESCs or iPSCs may have 
a new system for antigen presentation since these cells express very 
low level of MHC molecules on their cell surface (Li et al., 2009b). 
Further experimental studies are necessary for a better understand-
ing of the nature of iPSC as a new type of vaccine vector.
Cytokines are important signaling molecules that mediate com-
municative interactions both locally and between different cells 
in vivo. We have shown in our present study that irradiation of 
hiPSCs can selectively induce pro-inflammatory and Th1-related 
cytokines such as IL-1α, IL-12, and IL-18. Significantly, this was 
not  the  case  in  MRC5  fibroblasts.  Cytokine  production  from 
irradiated hiPSCs might promote the activation of APCs thereby 
enhancing cellular immunity against loaded antigen. IL-1α has 
been shown to be a potent pro-inflammatory cytokine and directly 
  hiPSCs, but not control supernatant, significantly induced the 
phosphorylation of IκB-α, indicative of nuclear factor-kappa B 
(NF-κB) activation (Figure 4F). A neutralizing antibody against 
IL-1α, but not control serum, was found to suppress this phos-
phorylation of IκB-α (Figure 4F), demonstrating that IL-1α from 
irradiated hiPSCs can activate NF-κB signaling in RAW 264.7 cells. 
These results indicate that ionizing radiation can effectively induce 
the production of IL-1α in hiPSCs for the activation of APCs and 
the antigen-specific immune responses.
disCussion
Our present findings uncover a novel function of hiPSCs in the 
generation of viral antigen-specific immune responses as a cell-
based vaccine. We found from our analyses that (1) Adenovirus 
system can effectively introduce exogenous viral antigen in hiP-
SCs without aberrant cell differentiation; (2) Radiation treatment 
can efficiently induce the cytokine production of IL-1α, IL-12, 
and IL-18; and (3) Inoculation of irradiated hiPSCs can enhance 
the antigen-specific cellular immune response even in xenogenic 
condition. These results indicate that hiPSCs can promote cellu-
lar immunity against an exogenously expressed viral antigen in a 
xenogenic condition.
We utilized the adenoviral vector system to express exogenous 
viral antigen in hiPSCs. Adenovirus has been shown previously to 
effectively transfer exogenous genes into hiPSCs (Tashiro et al., 2010) 
and we obtained a high efficiency in this regard without any effects 
upon cell differentiation. Moreover, >75% of the cells survived 
the adenoviral transduction which typically causes a   reasonable 
Figure 3 | Activation of mouse APCs by hiPSCs. (A,B) BALB/c mouse 
splenocytes were co-cultured with or without formalin-fixed (FF) or irradiated 
(IR) hiPSCs for 40 h, and the relative expression of CD86 (A) and MHC class II 
proteins (B) on the cell surface of CD11c+ splenocytes was monitored by flow 
cytometry. (C,D) BALB/c mouse splenocytes were seeded on transwell filters 
(0.4 μm pore) and co-cultured with irradiated or formalin-fixed hiPSCs in the 
bottom compartments for 40 h. The relative expression of CD86 (C) and MHC 
class II (D) was then monitored by flow cytometry. *P < 0.05.www.frontiersin.org  February 2011  | Volume 2  | Article 27  |  7
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the potent cross-reactivity of human IL-1α and IL-18 to stimu-
late mouse immune cells whereas the stimulatory effect of human 
IL-12 p35/p40 hetero-dimer to mouse cells has shown itself to be 
very marginal (Libert et al., 1990; Schoenhaut et al., 1992; Kong 
and Li, 2002). Although the precise molecular pathways underlying 
effective immune responses by hiPSCs have not been investigated, 
the irradiation-induced modulation of the cytokine expression in 
these stem cells might confer an effective adjuvant effect during 
the vaccination processes.
up-regulate NF-κB signaling resulting in the activation of dendritic 
cells and macrophages (Ardeshna et al., 2000; Yoshimura et al., 
2003; Weber et al., 2010). Although much progress has been made 
in dissecting the complexity of the cytokine network, the role of 
cytokines from pluripotent stem cells has not been well character-
ized. Our current results indicate however that the secretion of 
pro-inflammatory cytokines from hiPSCs might activate APCs via 
NF-κB activation to accelerate the induction of antigen-specific 
immune responses in vivo. Consistently, previous reports suggest 
Figure 4 | expression of immune-modulating cytokines in irradiated 
hiPSCs. (A) A scattered plot comparing the cytokine gene expression profiles of 
untreated and 15 Gy-irradiated hiPSCs (IR) . Arrows indicate the expression 
levels of IL -1α, IL -12A, and IL -18. The lines indicate the two-fold changes between 
the samples. (B,C) HiPSCs were either treated or not treated with 15 Gy ionizing 
radiation. Twenty-four hours later, total RNAs were isolated from untreated or 
irradiated hiPSCs followed by conventional RT-PCR (B) or quantitative RT-PCR 
(qPCR) (C). Data is normalized to the gapdh mRNA levels and represent the 
mean ± error of three independent experiments. *P < 0.05. (D) MRC5 
fibroblasts and hiPSCs were either untreated or treated with ionizing radiation 
(15 Gy). After 24 h, total RNAs were extracted and subjected to RT-PCR analysis 
for IL -1α, IL -12A, IL -18, and GAPDH. (e) Cell culture supernatants were collected 
from untreated or irradiated hiPSCs followed by IL -1α ELISA. Conditioned media 
from mouse embryonic fibroblasts (CM-MEFs) was used as a control. (F) 
Filtered culture supernatants from hiPSCs were premixed with rabbit 
anti-human IL -1α-neutralizing antibody or control rabbit sera for 2 h. RAW 264.7 
cells were then exposed to these mixtures (culture supernatant and antibody) 
for 10 min before preparing whole cell lysates for immunoblotting analysis with 
either anti-phosphorylated IκB-α (p-IkB-α) or anti-IκB-α antibodies. 
Lipopolysaccharide (LPS) was used as a positive control.Frontiers in Microbiology  | Virology    February 2011  | Volume 2  | Article 27  |  8
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In this report, we evaluated the immunogenicity of hiPSCs 
which expressed viral antigen in a mouse model. In the future, it 
is necessary to examine the potency of iPSCs in syn- or allogenic 
conditions using murine iPSCs. Additionally, the immunogenicity 
of non-iPSCs should be investigated in comparison with that of 
iPSCs. However, at least, even in the xenogenic condition, irradi-
ated hiPSCs expressing HIV-1 gp160 protein could induce antigen-
  specific cellular immune response. Our current results thus pro-
vide evidence for the capacity of hiPSCs to induce antigen-specific 
immunity against the viral proteins.
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